Chao Gao

Showing 1-3 of 3 articles

Interventions for valvular disease

Valvular heart interventions: advances from 2019 to 2020

Wang R, Gao C, Kawashima H, Modolo R, Rosseel L, Onuma Y, Soliman O, Serruys P, Mylotte D

September 22, 2020 | 10.4244/EIJ-D-20-00096

Coronary interventions

A randomized controlled trial to compare the safety and efficacy of sirolimus-eluting biodegradable polymer ultra-thin stent (SUPRAFLEX Cruz) and everolimus-eluting biodegradable polymer stent (SYNERGY) in treatment for three-vessel coronary artery disease: design of the Multivessel TALENT trial

Hara H, Gao C, Kogame N, Ono M, Kawashima H, Wang R, Morel M, O'Leary N, Sharif F, Möllmann H, Reiber J, Sabate M, Zaman A, Wijns W, Onuma Y, Serruys P

September 15, 2020 | 10.4244/EIJ-D-20-00772

The year in review: coronary interventions

Gao C, Wang R, Sharif F, Takahashi K, Ono M, Hara H, Tomaniak M, Kawashima H, Modolo R, van Geuns R, Capodanno D, Byrne R, Wijns W, Onuma Y, Serruys P

April 17, 2020 | 10.4244/EIJ-D-19-01124

1

Latest news

Focus on emerging physiology indices, TAVI, sizing with abnormal aortic cusps, a megaregistry of complex PCIs and more…

Tetralogy of Fallot with acquired double right ventricular outflow tract

September 18, 2020

Ahead of print: Leaflex Study

September 23, 2020

Integrating physiology in OCT

September 23, 2020

VOYAGER PAD, PARTNER 2A, ISCHEMIA and much more

(The Trials book is supported by Biotronik)

August 28, 2020

Guidance Papers

Guidelines, consensus & position papers

August 28, 2020

Steady-state hyperaemia

September 18, 2020

This Week's JAA's: Biograde Study, Advances in valvular heart interventions...

September 22, 2020

Valvular disease